Cargando…
Pricing Externalities to Balance Public Risks and Benefits of Research
How should scientific funders evaluate research with public health risks? Some risky work is valuable, but accepting too much risk may be ethically neglectful. Recent controversy over H5N1 influenza experiments has highlighted the difficulty of this problem. Advocates of the research claim the work...
Autores principales: | Farquhar, Sebastian, Cotton-Barratt, Owen, Snyder-Beattie, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576218/ https://www.ncbi.nlm.nih.gov/pubmed/28767274 http://dx.doi.org/10.1089/hs.2016.0118 |
Ejemplares similares
-
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
por: Vogler, Sabine, et al.
Publicado: (2019) -
The commercialization of university-based research: Balancing risks and benefits
por: Caulfield, Timothy, et al.
Publicado: (2015) -
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022) -
Overview of external reference pricing systems in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2015) -
When the Price Is Right: Beyond the Medical Risks and Benefits of Costly Therapies
por: Kittleson, Michelle M.
Publicado: (2022)